Stepping up its efforts to push products into the burgeoning molecular diagnostics market, Invitrogen last week licensed its Lux reagent technology to Prodesse, a Wisconsin-based developer of multiplex PCR-based diagnostic tests.
The alliance is the latest in a series of actions taken by Invitrogen to further develop a variety of technologies acquired during its 2004-2005 buying spree for the molecular diagnostics field. The pact also furthers Invitrogen’s plans to greatly expand its OEM business.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

CNBC reports that Amazon invested in the startup Grail as it sees an opportunity for its cloud computing company in genomics.

Researchers are working on re-making the yeast genome from scratch, according to the Associated Press.

Lawrence Krauss writes at Slate that science is needed for good public policy and should not be ignored.

In Cell this week: functional profiling of Plasmodium genome, a self-inactivating rabies virus, and more.